Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...

Shares of Gilead Sciences Inc. surged over 4% in premarket trading on Wednesday following a solid fourth-quarter earnings ...

Medicare is a vital resource for approximately 20% of the U.S. population, providing crucial health benefits to those who ...

It caps off the first full quarter with David Joyner, a longtime CVS executive, as CEO of the troubled retail drugstore chain ...

Monica Martin de Bustamante, senior partner and head of advisory at Trinity Life Sciences, spoke with Pharmaceutical ...

| With budget reconciliation right around the corner, different slices of the healthcare industry have made their views clear on issues like physician pay, ACA subsidies, telehealth flexibilities, ...

Lawmakers and providers need to step in before the program’s financial stability is threatened, Ron Williams, Diane Hansen, ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

If big pharma was hoping that there would not be drug price negotiations under President Trump, they seem to have had their hopes dashed. That ...

Explore how Medicare drug price negotiations under the Inflation Reduction Act could evolve with the Trump administration. Read more here.

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...